BELLEVUE, WA, Kona Medical today announced it has closed a Series D equity financing of $10 million led by Morningside Group.
BELLEVUE, WA, Kona Medical, Inc. (www.konamedical.com
) today announced it has closed a Series D equity financing of $10 million. Morningside Group, a broad-based investment firm with significant presence in China, led the investment and is the sole investor. 'These funds are earmarked for the China market,' said Michael Gertner, MD, founder and CEO of Kona Medical. 'Our research predicts a very large market in China for a non-invasive therapy to treat hypertension. This investment will allow Kona to begin navigating the complex clinical, regulatory, and intellectual property issues associated with this region. We are very pleased to have an experienced investor in the region join the Kona syndicate.'
'Kona Medical has tremendous potential,' said Reenie McCarthy for Morningside. 'We look forward to working with the company to bring this important therapy to market.'
About Kona Medical
Kona Medical's Surround Sound Renal Denervation System utilizes ultrasound, delivered from outside the body, to treat nerves leading to and from the kidney. Renal denervation has been shown in clinical studies to lead to significant and lasting reductions in blood pressure in drug-resistant hypertension patients. Kona's non-invasive system offers the opportunity to increase patient access to renal denervation and lower healthcare costs. Kona is based in Bellevue, Washington, and Menlo Park, California.
For additional information, please visit www.konamedical.com
Morningside is a diversified investment group founded in 1986 and engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, and across Asia-Pacific. Morningside is an active investor in early-stage life science companies formed around new technologies which represent a high degree of novelty over existing technologies. More information is available at www.morningside.com.
Note: Kona Medical's technology is investigational and is not yet for sale or approved by the US Food and Drug Administration.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about